CDNF protein treatment for Parkinsons’ disease developed by Herantis Pharma and the team of the Institute of Biotechnology was presented with the Innovation Award 2018 of the Chemical Industry Federation of Finland on 17 April 2018.

The CDNF protein treatment for Parkinson’s disease developed by Herantis Pharma and the team of the Institute of Biotechnology in the University of Helsinki has been presented with the Innovation Award 2018 of the Chemical Industry Federation of Finland.

The CDNF treatment has in animal models been shown to be an effective protector of neurons. It is not only alleviating symptoms, but it also halts the progress of the disease.

The development of the biological medical preform is now in the phase of placebo controlled clinical trials in European Parkinson’s research centres.

More about the Innovation Award